Phase 2 Stroke Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• The person joining (or their legal representative) has agreed to take part by signing a consent form before any trial procedures begin.
• Adults aged 18 to 80 years old at the time of signing the consent form.
• People who have been clinically diagnosed with an acute ischaemic stroke (a stroke caused by a blockage).
• People whose stroke symptoms began within 24 hours before enrolment — including "wake-up strokes," where the last time the person was known to be well was within 24 hours of enrolment.
• People whose stroke is rated as moderate to severe, based on a standard stroke severity scoring tool (a score of 6 to 25 on the NIH Stroke Scale).
• People who had little to no disability before this stroke, based on a standard disability scale (a Modified Rankin Scale score below 2 before the stroke).
• People whose stroke symptoms suggest the blockage is in the front part of the brain's blood supply (called the anterior circulation).
• People whose brain scan shows a blockage in one of several specific blood vessels in the brain (confirm with trial site for exact vessel details).
• People whose brain scan shows there is still brain tissue that could potentially be saved.

Who may not be able to join:

• People who weigh more than 130 kilograms or less than 40 kilograms.
• People who have had a severe traumatic brain injury in the past 90 days.
• People with a history of bleeding inside the brain (intracranial haemorrhage).
• People with a history of a brain tumour, except for a small, slow-growing type called a meningioma.
• People who have had a stroke in the past 90 days.
• People who have had brain or spinal surgery in the past 90 days.
• People who have had major surgery or a serious physical injury in the past 14 days.
• People with a history of a condition called cerebral amyloid angiopathy, which affects blood vessels in the brain.
• People with a history of cancer anywhere in the body, except for certain skin cancers (basal cell or squamous cell) that were fully removed with clear margins.
• People with a serious or terminal illness where life expectancy is estimated to be less than one year.
• People who have taken part in another interventional clinical trial within the past 90 days.
• People with a known severe allergic reaction to the study drug (TAK-755) or any of its ingredients.
• People who have previously received the study drug TAK-755 at any time.
• People who have received a drug called caplacizumab in the past 30 days.
• People who have received products containing von Willebrand factor in the past 14 days.
• People who, in the view of the trial doctor, are unable to understand what taking part in the trial involves (based on conditions present before this stroke).
• People who have already received certain clot-dissolving medications (such as alteplase, tenecteplase, prourokinase, or reteplase) for this stroke.
• People who, according to the trial site's standard guidelines, would be eligible to receive standard clot-dissolving medication for this stroke and where that treatment is directly available.
• People for whom the treating medical team plans to carry out a procedure to physically remove the clot (called endovascular thrombectomy), where that procedure is available.
• People who had a seizure at the time this stroke began.
• People whose blood pressure remains very high (systolic 185 mmHg or above, or diastolic 110 mmHg or above) before being assigned to a treatment group.
• People with blood sugar levels that are very low (below 50 mg/dL) or very high (above 400 mg/dL).
• People with active, uncontrolled bleeding.
• People with a condition that causes difficulty with blood clotting or that would raise the risk of serious bleeding.
• People who are unable to have a brain scan (MRI or CT).
• People whose stroke symptoms are improving rapidly on their own.
• People whose brain artery blockage is long-standing rather than caused by a new event.
• People with a complete blockage of the main artery in the neck (extracranial internal carotid artery) that is causing this stroke.
• People whose scan shows signs of infection-related clots or a heart valve infection (septic emboli or bacterial endocarditis).
• People with another significant medical condition that, in the trial doctor's opinion, would put them at additional risk.
• People who are pregnant, breastfeeding, or who are unable to use the birth control methods required by the trial protocol (in the opinion of the trial doctor).
• People whose brain scan images are too poor in quality to be assessed according to the trial's requirements.
• People whose brain scan shows significant swelling or shifting of brain structures.
• People whose scan shows a blockage affecting more than one area of the brain's blood supply.
• People whose scan shows any bleeding in the brain, whether new or old.
• People whose scan shows that a large area of the brain (more than one-third of a major territory called the middle cerebral artery territory) has already been affected.
• People whose scan shows a brain tumour (other than a small meningioma), a brain aneurysm, or an abnormal tangle of blood vessels (arteriovenous malformation).
• People with a very low platelet count (below 50,000 per cubic millimetre), as platelets help blood to clot.
• People who the trial doctor believes may be unable or unwilling to follow the trial procedures.

Important: Always verify eligibility with the trial site directly before applying.